AKT1 and cancer: As the phosphatidyl-inositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is aberrantly activated in many tumour types, mTOR suppression is regarded to be an attractive approach for cancer therapy [1].